CureMetrix Logo
“As the former Deputy Secretary for Integration and Development of the Health Sector in Mexico, I know the challenges our health system faces given how few specialized radiologists in mammography there are in our country. A technology like this will help our radiologists serve infinitely more women
LA JOLLA, Calif. (PRWEB) December 15, 2017
CureMetrix® S.A. de C.V., a subsidiary of CureMetrix, Inc., a company developing a physics-based, deep learning algorithm that allows radiologists to get more specific readings on breast images, signs its first agreement in Mexico to assist with early and accurate detection of breast cancer in mammograms.
After securing international funding and engaging with strategic partners, CureMetrix S.A. de C.V. deploys a Software as a Service (SaaS) to Segunda Lectura, an international company specializing in medical image reading and second opinions. This adoption of the CureMetrix computer aided detection (CAD) service—a CAD That Works™—makes Segunda Lectura the first clinic in Mexico to provide enhanced mammogram reads using artificial intelligence.
“As the former Deputy Secretary for Integration and Development of the Health Sector in Mexico, I know the challenges our health system faces given how few specialized radiologists in mammography there are in our country. A technology like this will help our radiologists serve infinitely more women at a much lower cost,” says Eduardo Gonzalez-Pier.
In partnership with two major venture capital partners – Innova Salud, investors focusing on bringing the best healthcare solutions to the market, and XB Ventures, investors identifying cross-border technology to bring into Mexico – CureMetrix was able to enter the Mexican market and form relationships with businesses on the frontline of delivering mammography to patients.
“Breast cancer is a global issue and we’re tackling it in a country where we can have the greatest impact quickly,” explained Kevin Harris, CEO of CureMetrix. “We are thrilled about this collaboration and are looking forward to expanding into many other hospitals, clinics and breast centers throughout Mexico.”
Renee Almaraz, CEO of Segunda Lectura, commented, “the collaboration is critical to helping Segunda Lectura become the highest quality second opinion provider that anyone can access throughout the country. We will be able to detect cancer earlier, reduce unnecessary recalls and biopsies, and improve the patient experience.” In conjunction with her business partner and Chief Medical Officer, Dr. Paola Gonzalez Balboa, Segunda Lectura is utilizing the CureMetrix artificial intelligence and deep learning service to assist with detection, quantification, triaging and diagnosis of anomalies to improve their clinical outcomes and optimize their radiologists’ workflows.
Dr. Paola Gonzalez-Balboa is using cmAssist™ CAD markings in her initial screenings and second reads. “The service operates at both a high sensitivity and high specificity showing only the true positive marks on the images and quantifying them on a degree of suspicion,” she states. This enables her to read a higher volume of mammograms each day and to detect breast cancer earlier and more accurately than she could without CureMetrix.
About CureMetrix
CureMetrix® was founded in 2014 on the belief that better medical image analysis technology could lead to better outcomes for breast cancer patients. The company is developing investigational physics-based artificial intelligence and deep machine learning solutions to help radiologists get more accurate readings of breast images. Through its research partnerships with leading hospital radiology departments, CureMetrix has evaluated more than 500,000 mammogram images to identify potential false negatives, which are undiagnosed cancers, and false positives, which are unnecessary recalls of patients to review anomalies that turn out to be normal. False negatives can occur at a rate of about one in five breast cancers.1 False positives affect 7-12 percent of all women after an initial mammogram.2 Reducing false positives could save a significant portion of the $4 billion per year spent on unneeded and sometimes invasive procedures such as biopsies.3 More importantly, reducing false negatives could save lives as well as reduce the cost and difficulty of cancer treatment through early detection.
CureMetrix S.A. de C.V was founded in 2017 in Mexico City as a subsidiary of CureMetrix with the goal of providing advanced, artificial-intelligence based services to private and public health care providers in Mexico.
Our goal is to create CAD that Works®. Improving computer-aided diagnosis (CAD) through a more robust physics-based algorithm for detecting and diagnosing breast and all cancers empowers radiologists, supports their patients and reduces costs while improving clinical outcomes. To learn more about CureMetrix, visit http://www.curemetrix.com.
1 https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/limitations-of-mammograms.html
2 http://ww5.komen.org/BreastCancer/AccuracyofMammograms.html
3 http://content.healthaffairs.org/content/34/4/576.abstract
Media Contact:
Elise Crispen
Director of Marketing, CureMetrix
elise(at)curemetrix(dot)com
619-857-8212